391
Participants
Start Date
March 31, 2022
Primary Completion Date
September 28, 2023
Study Completion Date
September 28, 2023
ALT-801
Injected subcutaneously (SC)
Placebo
Injected subcutaneously (SC)
Altimmune CTM, New York
Cornell University, Joan and Sanford Weill Medical College, New York
Altimmune CTM, Philadelphia
Altimmune CTM, Savannah
Altimmune CTM, Port Orange
Altimmune CTM, Jacksonville
Altimmune CTM, Sunrise
Altimmune CTM, Boca Raton
Altimmune CTM, Clearwater
Altimmune CTM, Fort Myers
Altimmune CTM, Birmingham
Altimmune CTM, Knoxville
Altimmune CTM, Louisville
Altimmune CTM, Cincinnati
Altimmune CTM, Indianapolis
Midwest Institute for Clinical Research, Indianapolis
Altimmune CTM, Butte
Altimmune CTM, Evanston
Altimmune CTM, Kansas City
Altimmune CTM, New Orleans
Altimmune CTM, Baton Rouge
Altimmune CTM, Bellaire
Altimmune CTM, San Antonio
Altimmune CTM, Austin
Altimmune CTM, St. George
Altimmune CTM, Mesa
Altimmune CTM, Los Angeles
National Research Institute, Los Angeles
Altimmune CTM, Montclair
Altimmune CTM, Santa Barbara
Altimmune CTM, Berlin
Lead Sponsor
Altimmune, Inc.
INDUSTRY